News
STATEMENT: 3P Biopharmaceuticals shows its commitment against Covid-19
We are living in difficult times due to the COVID19 pandemic, and it is in these times of serious difficulty that 3P Biopharmaceuticals shows its maximum commitment to its employees and to society.
Read more
3P Biopharmaceuticals joins International Day of Women and Girls in Science
At 3P Biopharmaceuticals we celebrate the International Day of Women and Girls in Science, and we want to do so by appreciating and thanking each of the women that forms part of the 3P team
Read more
Validation batches of the vaccine against equine strangles Strangvac® is completed
3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®
Read more
First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease
3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use.
Read more
A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals
3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment
Read more
3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment
3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished a tech transfer
Read more
The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan
The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice)
Read more
3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder
3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor
Read more
3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment
3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment
Read more